Interactive Features

Quiz

Examining the Efficacy of Azacitidine Plus Ruxolitinib in Myelofibrosis Treatment

07/03/2024

Oncology

Quiz

Effect of Momelotinib on Symptom Benefits Among Patients With Myelofibrosis

02/28/2024

True or False: Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that demonstrated insight into the appropriateness of the symptom change threshold used in the phase 3...

True or False: Momelotinib...

02/28/2024

Oncology

Quiz

Parsaclisib Plus Stable-Dose Ruxolitinib for Myelofibrosis

02/27/2024

The addition of parsaclisib to stable-dose ruxolitinib treatment ___ splenomegaly and ___ symptom scores among patients with primary or secondary myelofibrosis who did not have optimal responses to ruxolitinib alone, according to findings...

The addition of parsaclisib to...

02/27/2024

Oncology

Quiz

5-Year Survival and Efficacy of Ropeginterferon for Low-Risk Polycythemia Vera

02/13/2024

What was the main finding of a phase 2 trial on the 5-year survival and efficacy of ropeginterferon among patients with low-risk polycythemia vera?

What was the main finding of a...

02/13/2024

Oncology

Quiz

Survival Outcomes Among High-Risk Patients With MF Treated With Ruxolitinib

01/31/2024

What was the key finding of a population-based retrospective cohort study analyzing the outcomes of higher-risk patients with myelofibrosis treated with ruxolitinib in an unselected real-world population?

What was the key finding of a...

01/31/2024

Oncology

Quiz

Treating High-Risk Philadelphia-Negative MPNs With Ropeginterferon Alfa-2B

01/31/2024

True or False: Findings from a retrospective observational study show that ropeginterferon alfa-2b demonstrated high response rates and tolerable safety among young high-risk patients with Philadelphia chromosome-negative myeloproliferative...

True or False: Findings from a...

01/31/2024

Oncology

Quiz

Ruxolitinib for Elderly JAK Inhibitor-Naïve Patients With Myelofibrosis

01/16/2024

True or False: Interim results from the phase 4 JAKoMO trial indicated that ruxolitinib demonstrated safety and efficacy among elderly Janus kinase (JAK) inhibitor-naïve patients with myelofibrosis in the real-world setting.

True or False: Interim results...

01/16/2024

Oncology

Quiz

Treating JAK-Naive Patients With Myelofibrosis With Pelabresib Plus Ruxolitinib

01/05/2024

What was the key finding of the MANIFEST-2 trial on the combination of pelabresib and ruxolitinib among patients with JAK-naïve myelofibrosis?

What was the key finding of the...

01/05/2024

Oncology

Quiz

Impact of Inflammatory Comorbidities on Myelofibrosis Disease Risk

01/05/2024

True or False: According to a retrospective analysis of younger patients with myelofibrosis (MF), inflammatory comorbidities were correlated with increased disease risk and decreased survival.

True or False: According to a...

01/05/2024

Oncology

Quiz

Treating Myelofibrosis With Pacritinib

12/06/2023

True or False: Pacritinib demonstrated consistent efficacy for spleen and symptom response among patients with myelofibrosis (MF), regardless of cytopenias.

True or False: Pacritinib...

12/06/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology